📉 The Financial Deep Dive
The Numbers:- 9MFY26 (ended Dec 31, 2025):
- Consolidated Revenue: ₹15,134 Mn (+11.2% YoY)
- EBITDA: ₹6,712 Mn (+22.6% YoY)
- EBITDA Margin: 41.5%
- Profit After Tax (PAT): ₹4,020 Mn (+9.1% YoY)
- Q3FY26 (ended Dec 31, 2025):
- Consolidated Revenue: ₹4,232 Mn (-15.0% YoY, -23.1% QoQ)
- EBITDA: ₹1,907 Mn (+3.7% YoY, -28.3% QoQ)
- Profit After Tax (PAT): ₹928 Mn (-25.3% YoY, -46.5% QoQ)
- PAT Margin: 20.3%
- The company reported strong growth in its nine-month financials, driven by the CRDMO business, which saw revenue rise 13.1% YoY to ₹12,599 Mn. Specialty Ingredients contributed ₹2,535 Mn, up 2.5% YoY.
- However, the third quarter presented a significant downturn, with revenue and PAT declining sharply YoY and QoQ.
- An exceptional item of ₹254 Mn was recognized in 9MFY26, related to a provision for new Labour Codes, impacting Profit Before Tax and PAT.
- Anthem Biosciences maintained a healthy net cash position of ₹12,312 Mn as of December 31, 2025.
- The most striking omission was the complete lack of forward-looking management guidance or outlook in the press release, leaving investors with no clarity on future expectations or growth drivers.
🚩 Risks & Outlook
Specific Risks:
- The sharp deceleration in Q3 FY26 performance, especially the revenue and PAT decline, signals potential short-term headwinds.
- The absence of any management guidance creates significant uncertainty regarding future growth trajectory and profitability.
- The provision for new Labour Codes could imply future cost increases, impacting margins.
- Slower growth in the Specialty Ingredients segment needs monitoring.
- Investors will be keen to understand the reasons behind the Q3 slump and what steps the company plans to take to arrest the decline. The lack of a stated outlook means scrutiny will be intense on the next quarterly results to gauge a potential recovery.